Literature DB >> 10201434

Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy.

V Fetoni1, P Soliveri, D Monza, D Testa, F Girotti.   

Abstract

The objective was to determine the extent to which psychiatric disturbances (especially mood disorders) generally considered poor prognostic factors, are present in patients with striatonigral (SND) type multiple system atrophy (MSA) compared with patients with idiopathic Parkinson's disease (IPD). The Hamilton depression scale (HAM-D), brief psychiatric rating scale (BPRS), and Unified Parkinson's disease rating scale (UPDRS) were administered to clinically probable non-demented patients with SND-type MSA and patients with IPD matched for age and motor disability, at baseline and after receiving levodopa. At baseline total HAM-D score was greater in patients with IPD. Overall, BPRS score did not differ between the two groups; however, patients with IPD scored higher on anxiety items of the BPRS, and patients with MSA had higher scores on the item indicating blunted affect. After levodopa, both groups improved significantly in UPDRS and HAM-D total scores (just significant for patients with MSA). Patients with IPD improved significantly in total BPRS score but patients with MSA did not. At baseline patients with IPD were more depressed and anxious than patients with MSA who, by contrast, showed blunted affect. After levodopa, depression and anxiety of patients with IPD improved significantly whereas the affective detachment of patients with MSA did not change. Major neuronal loss in the caudate and ventral striatum, which are part of the lateral orbitofrontal and limbic circuits, may be responsible for the blunted affect not responsive to levodopa therapy found in patients with MSA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201434      PMCID: PMC1736312          DOI: 10.1136/jnnp.66.4.541

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  D Aarsland; K Karlsen
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 2.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

Review 3.  Subdomains within the negative symptoms of schizophrenia: commentary.

Authors:  Brian Kirkpatrick; Bernard Fischer
Journal:  Schizophr Bull       Date:  2006-02-21       Impact factor: 9.306

4.  The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease.

Authors:  Elizabeth L Birchall; Harrison C Walker; Gary Cutter; Stephanie Guthrie; Allen Joop; Raima A Memon; Ray L Watts; David G Standaert; Amy W Amara
Journal:  Brain Stimul       Date:  2016-12-27       Impact factor: 8.955

Review 5.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 6.  Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.

Authors:  Iva Stankovic; Florian Krismer; Aleksandar Jesic; Angelo Antonini; Thomas Benke; Richard G Brown; David J Burn; Janice L Holton; Horacio Kaufmann; Vladimir S Kostic; Helen Ling; Wassilios G Meissner; Werner Poewe; Marija Semnic; Klaus Seppi; Atsushi Takeda; Daniel Weintraub; Gregor K Wenning
Journal:  Mov Disord       Date:  2014-04-18       Impact factor: 10.338

7.  Progression of parkinsonism in multiple system atrophy.

Authors:  Klaus Seppi; Farid Yekhlef; Anja Diem; Elisabeth Luginger Wolf; Joerg Mueller; François Tison; Niall P Quinn; Werner Poewe; Gregor K Wenning
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

8.  Multiple system atrophy: current and future approaches to management.

Authors:  Olivier Flabeau; Wassilios G Meissner; François Tison
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

9.  Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.

Authors:  Karen L Eskow Jaunarajs; Kristin B Dupre; Corinne Y Ostock; Thomas Button; Terrence Deak; Christopher Bishop
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

Review 10.  Parkinson's disease and anxiety.

Authors:  K Walsh; G Bennett
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.